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Abstract In mesial temporal lobe epilepsy (MTLE),
spontaneous seizures likely originate from a multi-struc-
tural epileptogenic zone, including several regions of the
limbic system connected to the hippocampal formation. In
this study, we investigate the structural connectivity
between the supramammillary nucleus (SuM) and the
dentate gyrus (DG) in the model of MTLE induced by
pilocarpine in the rat. This hypothalamic nucleus, which
provides major extracortical projections to the hippocam-
pal formation, plays a key role in the regulation of several
hippocampus-dependent activities, including theta
rhythms, memory function and emotional behavior, such as
stress and anxiety, functions that are known to be altered in
MTLE. Our findings demonstrate a marked reorganization
of DG afferents originating from the SuM in pilocarpine-
treated rats. This reorganization, which starts during the
latent period, is massive when animals become epileptic
and continue to evolve during epilepsy. It is characterized
by an aberrant distribution and an increased number of
axon terminals from neurons of both lateral and medial
regions of the SuM, invading the entire inner molecular
layer of the DG. This reorganization, which reflects an
axon terminal sprouting from SuM neurons, could con-
tribute to trigger spontaneous seizures within an altered
hippocampal intrinsic circuitry.
Keywords Hippocampus  Dentate gyrus  GAD 
VGAT  VGLUT2  Hypothalamus  SuM
Introduction
Mesial temporal lobe epilepsies (MTLEs) are among the
most common forms of drug-resistant partial epilepsy in
adults (Engel 1996). These epilepsies are often associated
with an antecedent brain insult, such as prolonged febrile
seizures, status epilepticus, brain trauma or meningitis, and
with hippocampal sclerosis (HS) (Wieser 2004). These
observations have led to the concept that MTLE results
from an aberrant hippocampal network triggered by an
initial brain insult. However, many electro-clinical studies
provide evidence that the abnormal network responsible for
seizure generation, the epileptogenic zone, cannot be
restricted to the hippocampal formation. In MTLE, seizures
originate from a multi-structural epileptogenic zone, which
involves several limbic structures of the temporal lobe
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including the hippocampus, the amygdala and the entorh-
inal cortex (For review see Kahane and Bartolomei 2010).
Animal models of MTLE including the pilocarpine
model of chronic limbic seizures demonstrate that an initial
brain insult caused by status epilepticus leads to a complex
time-dependent reorganization of the intrinsic gamma-
aminobutyric acid (GABA)-ergic (Obenaus et al. 1993;
Houser and Esclapez 1996; Esclapez et al. 1997; Esclapez
and Houser 1999; Cossart et al. 2001; Dinocourt et al.
2003; Kobayashi and Buckmaster 2003; Sloviter et al.
2003; Peng et al. 2013) and glutamatergic (Mello et al.
1993; Okazaki et al. 1995; Esclapez et al. 1999; Lehmann
et al. 2001; Okazaki and Nadler 2001; Buckmaster et al.
2002; Dashtipour et al. 2003; Sloviter et al. 2003; Boulland
et al. 2007; Jiao and Nadler 2007; Ribak et al. 2012) hip-
pocampal networks. These complex reorganizations of the
hippocampal intrinsic neuronal networks lead to a marked
homeostatic unbalance between excitation and inhibition
not only during the chronic stage (Cossart et al. 2001; El-
Hassar et al. 2007) but also during the latent period when
the animals do not yet display spontaneous seizures (Ko-
bayashi and Buckmaster 2003; El-Hassar et al. 2007).
Furthermore, the ratio of the glutamatergic drive to the
overall synaptic drive received by CA1 pyramidal cells
during the latent period is not further modified in epileptic
animals (El-Hassar et al. 2007). This suggests that the
reorganization of hippocampal intrinsic networks is not
sufficient by itself to generate seizures. Therefore, in this
animal model, the epileptogenic zone likely involves
broader reorganizations within and between different brain
regions of the limbic system.
In this study, we examined a potential reorganization
of the connectivity between the hypothalamus and the
hippocampal formation, more specifically the hippocam-
pal afferents from the supramammillary region (SuM),
which is the main hypothalamic structure innervating the
hippocampal formation. This hypothalamic region is
involved in the regulation of hippocampal theta rhythms
(Kirk and McNaughton 1991, 1993; Kocsis and Vertes
1994; Vertes and Kocsis 1997; Kocsis and Kaminski
2006) and therefore plays a crucial role in the control of
several hippocampus-dependent cognitive functions but
also emotional behavior, including stress and anxiety
(Pasquier and Reinoso-Suarez 1976; Richmond et al.
1999; Pan and McNaughton 2002; Santin et al. 2003; Pan
and McNaughton 2004; Shahidi et al. 2004). Interestingly,
it is known that hippocampal theta rhythms and hippo-
campus-dependent memory functions are altered in the
pilocarpine model of MTLE (Chauvie`re et al. 2009;
Marcelin et al. 2009) as well as in human MTLE (Bettus
et al. 2008) and that in these epilepsies, the occurrence of
seizures is particularly sensitive to stress (Lanteaume
et al. 2009).
Although studies in human MTLE (Maglo´czky et al.
2000) and a related animal model (Skyers et al. 2003) have
suggested axonal sprouting of SuM neurons as one possible
explanation for an increase in calretinin- and l-opioid
receptor-labeled terminals in the dentate gyrus, respec-
tively, such actual growth and reorganization of SuM–
hippocampal pathways remain to be demonstrated. The
current study was designed to address this issue as well as
to determine the time course of these potential structural
reorganizations at the different stages of development of
the pilocarpine-induced epilepsy (latent and chronic
stages). For this purpose, we performed anterograde-trac-
ing experiments in combination with immunohistochemi-
cal experiments for the vesicular glutamate transporter 2
(VGLUT2, Fremeau et al. 2001; Herzog et al. 2001), the
synthesizing enzyme for GABA, glutamic acid decarbox-
ylase 65 (GAD65, Esclapez et al. 1993, 1994) and the
vesicular GABA transporter (VGAT, McIntire et al. 1997;
Chaudhry et al. 1998), to discriminate fibers and axon
terminals, originating from the different SuM regions.
Indeed in naı¨ve rat, the distinct SuM–hippocampal path-
ways can be differentiated, based on their anatomical and
neurochemical features. The first pathway originates from
neurons in the lateral region of the SuM (SuML) and
innervates the supragranular layer of the dorsal dentate
gyrus (DG) and, to a much lesser extent, the ventral DG
(Haglund et al. 1984; Maglo´czky et al. 1994; Vertes and
McKenna 2000). This pathway displays a unique gluta-
matergic and GABAergic dual neurotransmitter phenotype.
Its axon terminals co-express VGLUT2, GAD65 and
VGAT (Soussi et al. 2010). The second pathway originates
from neurons in the most posterior and medial part of the
SuM (SuMM) and innervates the inner molecular layer of
the ventral DG exclusively (Vertes 1992; Maglo´czky et al.
1994) as well as the CA2/CA3a pyramidal cell layer
(Maglo´czky et al. 1994). The axon terminals from the
SuMM contain VGLUT2 only (Soussi et al. 2010). To
ascertain the neuronal source and targets of observed
aberrant connectivity in pilocarpine-treated animals, we
performed additional experiments including in situ
hybridization for VGLUT2 mRNA as well as retrograde-
tracing methods with rabies virus and immunohistochem-
ical labeling for the neuron-specific nuclear protein
(NeuN).
Materials and methods
Animal care and experimental procedures were per-
formed in accordance with the European Community’s
Council Directive 86/609/EEC and were approved by
Aix-Marseille University Chancellor’s Animal Research
Committee.
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Animals and pilocarpine treatment
Young adult male Wistar rats (180–200 g; Charles River,
France) were injected with a low dose of methyl scopol-
amine nitrate (1 mg/kg, i.p.; Sigma, St Louis, MO), in
order to minimize the peripheral effects of the pilocarpine
hydrochloride (340 mg/kg; i.p.; Sigma) provided 30 min
later to induce status epilepticus (SE). The period of SE
was alleviated after 2 h with diazepam (8 mg/kg, i.p.;
Roche, Boulogne-Billancourt, France). Pilocarpine-treated
animals (n = 20) were observed periodically for general
behavior and occurrence of spontaneous seizures. These
animals were studied at several post-SE intervals: at 1 and
2 weeks, when animals displayed an apparently normal
behavior (n = 3 at each interval), and at 2, 4 and
12 months, when the animals have developed spontaneous
recurrent seizures (n = 5, 6 and 3, respectively). We pre-
viously demonstrated, using the same experimental con-
ditions and continuous in vivo electroencephalographic
recordings, that in these pilocarpine-treated rats, the first
spontaneous seizures occur during the second or third week
(range 12 and 18th day) after SE (Marcelin et al. 2009).
Each group of pilocarpine-treated animals (1, 2 weeks, 2, 4
and 12 months) was compared to a group of age-matched
untreated rats (controls; n = 15).
Anterograde tracer injections
The anterograde tracer, Biotin-Dextran-Amine (BDA 2 %;
MW 3,000; Invitrogen, Carlsbad, CA), was injected under
stereotaxic condition into the SuML and SuMM according
to previously described protocol (Soussi et al. 2010).
Control (n = 6) and pilocarpine-treated rats at 2 and
4 months (n = 6) were anesthetized with chloral hydrate
(400 mg/kg; i.p.; Fisher Scientific, Loughborough, UK),
secured in a stereotaxic frame (David Kopf, Tujunga, CA)
and pressure-injected with 300 nL (30 nL/min during
10 min) of BDA either into the SuML at the following
coordinates: 3.9–4 mm posterior to bregma (AP),
0.5–0.7 mm lateral to the midline (L) and 8.9–9 mm ven-
tral to the cortical surface (V) or into the SuMM at the
following coordinates: AP = 4.3–4.7 mm L = 0.2 mm
and V = 8.8 mm. After the completion of injection pro-
cedures, the syringe was removed and the skin sutured. The
animals were treated with topical anesthetic and then
returned to their home cages for a survival period of
8–10 days to allow proper anterograde transport of the
tracer.
Rabies virus retrograde tracer
Rabies virus (RV) retrograde tracings were performed in
order to obtain a Golgi-like labeling (Salin et al. 2008) of
DG granule cells. Vaccinated personnel conducted all
experiments at the appropriate biosafety containment level.
The strain of RV used in this study was the Challenge
Virus Standard (CVS) (Bras et al. 2008; Ugolini 2010;
Coulon et al. 2011). The virus stock as cell culture super-
natant in minimal essential medium (4.107 plaque-forming
units/mL) was kept frozen at -80 C until use.
Under chloral hydrate general anesthesia, pilocarpine-
treated rats (n = 2, at 2 months) were pressure-injected
under stereotaxic condition within the stratum lucidum of
the CA3b region in the dorsal hippocampus with RV at a
200 nL final volume. After completion of the injection
procedures, the syringe was removed and the skin was
sutured. The animals were treated with local anesthetic,
returned to their cages kept at the appropriate biosafety
containment level for a survival period of 42 h to observe
an optimal RV retrograde labeling of the dendritic arbor of
dentate granule cells.
Tissue preparation
Rats were deeply anesthetized with choral hydrate
(500 mg/kg; Fisher Scientific) and transcardially perfused
with 4 % paraformaldehyde in 0.12 M sodium phosphate
buffer, pH 7.4 (PB). The brains were removed from the
skull, post-fixed for 1 h at room temperature (RT), rinsed
in PB, cryoprotected in 20 % sucrose overnight, frozen on
dry ice and sectioned coronally at 40 lm with a cryostat.
Every tenth section was stained with cresyl violet in order
to determine the general histological characteristics of the
tissue within the rostro-caudal extent of the brain. From
each rat, selected sections were processed for (1) immu-
nohistochemical labeling for VGLUT2; (2) detection of
tracers; (3) multiple labeling for detection of the antero-
grade or retrograde tracers and immunohistochemical
detection of VGAT or GAD65 and VGLUT2; (4) double
labeling for detection of NeuN and VGLUT2; and (5)
nonradioactive in situ hybridization using VGLUT2 cRNA
as a probe. Sections from control and pilocarpine-treated
animals were always processed in parallel.
Detection of the BDA anterograde tracer
The BDA-containing fibers and axon terminals were
visualized using the avidin–biotin–peroxidase method as
previously described (Soussi et al. 2010). Free-floating
sections were pre-treated in 1 % H2O2 for 30 min, rinsed
several time in 0.02 M potassium phosphate-buffered sal-
ine (KPBS, pH 7.2–7.4), then incubated overnight at RT in
an avidin–biotinylated–peroxidase complex (Vectastain
Elite ABC, Vector laboratories, Burlingame, CA) diluted
1:100 in KPBS containing 0.3 % Triton X-100 (Sigma).
The following day, after several rinses in KPBS, sections
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from control and pilocarpine-treated animals were pro-
cessed for 15 min in 3,30-diaminobenzidine-HCl (DAB
Sigma fast tablets; Sigma). Sections were subsequently
mounted onto superfrost plus slides (Thermo scientific,
Brunswick, Germany), dehydrated and coverslipped with
Permount (Electron Microscopy Sciences, Washington,
PA).
Immunohistochemistry
Single immunohistochemical labeling for VGLUT2
Free-floating sections were processed for immunohisto-
chemistry according to previously described protocol
(Esclapez et al. 1994). Sections were pre-treated for
30 min in 1 % H2O2, rinsed in PB and KPBS, pre-
incubated for 1 h in 3 % normal goat serum (NGS,
Vector Laboratories) diluted in KPBS containing 0.3 %
Triton X-100 and incubated overnight at RT in VGLUT2
rabbit polyclonal antiserum (1:5,000; Synaptic Systems,
SYSY, Gottingen, Germany) diluted in KPBS containing
1 % NGS and 0.3 % Triton X-100. After several rinses
in KPBS, sections were incubated for 1 h at RT in
biotinylated goat anti-rabbit immunoglobulin G (IgG;
Vector Laboratories) diluted 1:200 in KPBS containing
3 % NGS and then for 1 h at RT in Vectastain Elite
ABC diluted 1:100 in KPBS. Sections from control and
pilocarpine-treated rats were processed for the same
period of time (15 min) in DAB, rinsed in KPBS,
mounted onto Superfrost Plus slides, dehydrated and
coverslipped with Permount.
Simultaneous immunohistochemical detection for NeuN
and VGLUT2
Sections were pre-treated in 1 % H2O2 for 30 min, rinsed
several times in PB and KPBS and pre-incubated for 1 h in
KPBS containing 1 % blocking reagent (BR, Bœrhinger
Manheim, Germany) and 0.3 % Triton X-100. Then, they
were incubated overnight in a mixture of VGLUT2 rabbit
antiserum (1:5,000) and NeuN mouse monoclonal antibody
(1:4,000; Millipore, Temecula, CA) diluted in KPBS con-
taining 0.5 % BR and 0.3 % Triton X-100. The following
day, sections were first processed for detection of VGLUT2
as described above. After extensive rinses in KPBS, sec-
tions were processed for detection of NeuN. They were
incubated for 1 h in biotinylated horse anti-mouse IgG
(1:200; Vector laboratories) diluted in KPBS containing
0.5 % BR, rinsed in KPBS, then incubated for 1 h in avi-
din–biotin–alkaline phosphatase complex diluted in KPBS,
and finally revealed for 10 min in Fast Red (Fast Red
tablets, Sigma) diluted in 0.1 M Tris–HCl buffer (TB, pH
8.2). Sections were mounted onto Superfrost slides and
coverslipped with Crystal Mount (Biomeda, Foster City,
CA).
Multiple immunofluorescence labeling for BDA or Rabies
virus, VGLUT2 and GAD65 or VGAT
Free-floating sections were processed for multiple immu-
nofluorescence as previously described (Soussi et al. 2010).
Briefly, they were rinsed in KPBS, then incubated for 1 h
at RT in 3 % normal donkey serum (NDS, Jackson
ImmunoResearch Laboratories, Suffolk, UK) and diluted in
KPBS containing 0.3 % Triton X-100. For simultaneous
detection of BDA, VGLUT2 and VGAT or GAD65, sec-
tions were incubated overnight at RT in a solution con-
taining goat anti-biotin (1:200; Vector Laboratories),
guinea pig anti-VGLUT2 (1:5,000; Millipore) and rabbit
anti-VGAT (1:2,000; SYSY) or mouse anti-GAD65
(1:100; MAB 351R, Millipore) diluted in KPBS containing
0.3 % Triton X-100 and 1 % NDS. After several rinses in
KPBS, they were incubated for 2 h in Alexa 488-conju-
gated donkey anti-goat IgG (1:100; Invitrogen, Burlin-
game, CA), Cy5-conjugated donkey anti-guinea pig IgG
(1:100; Jackson ImmunoResearch Laboratories) and Cy3-
conjugated donkey anti-rabbit IgG or anti-mouse IgG
(1:100; Jackson ImmunoResearch Laboratories) diluted in
KPBS. For simultaneous detection of RV, VGLUT2 and
VGAT, sections were incubated overnight at RT in a
solution containing mouse anti-RV (1:5,000; Raux et al.
1997), guinea pig anti-VGLUT2 (1:5,000) and rabbit anti-
VGAT (1:2,000) diluted in KPBS containing 0.3 % Triton
X-100 and 1 % NDS and then for 2 h in Alexa 488-con-
jugated donkey anti-mouse IgG (1:100), Cy5-conjugated
donkey anti-guinea pig IgG (1:100, Jackson ImmunoRe-
search Laboratories) and Cy3-conjugated donkey anti-
rabbit IgG. All sections were mounted on superfrost-coated
slides, dried and coverslipped with Gel/Mount (Biomeda).
Controls
In all cases, no cross-reactivity was detected when one or
two of the primary antibodies were omitted.
Sections were analyzed either with a Leica TCS SP
(Leica, Wetzlar Germany) or a Zeiss LSM 5 Pascal (Zeiss,
Jena, Germany) laser-scanning microscopes using sequen-
tial acquisition of separate wavelength channels to avoid
fluorescence cross talk. Single confocal optical slices and
z-stacks of 10–25 confocal optical slices (2,048 9 2,048
pixels) spaced 200–300 nm were acquired with a 100X
objective (oil immersion, 1.4 numerical aperture), a
numerical zoom 2 (37.8 nm/pixel) or zoom 8 (9.4 nm/
pixel) and with the pinhole set at 1 Airy unit. Images were
displayed with the NIH ImageJ software (Abra`moff et al.
2004).
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Quantification of VGLUT2 and VGLUT2–VGAT
immunolabeling
Quantification of bouton densities from BDA-tracing
experiments does not allow comparative analysis between
animals. Indeed, the number of BDA-labeled fibers and
boutons may vary for each animal depending on tracer
uptake efficiency by the neurons (amount of labeled cells).
Therefore, in the DG, the densities of boutons, originating
from SuML and SuMM neurons, were estimated by the
densities of axon terminals displaying SuML and SuMM
neurochemical phenotype, i.e., labeled for VGLUT2/
VGAT and VGLUT2 only, respectively. The densities of
VGLUT2/VGAT- and VGLUT2 only labeled terminals
were assessed by the quantification of immunolabeling for
VGLUT2/VGAT and VGLUT2 only, respectively. These
analyses were performed on sections from both control
(n = 3) and 4-month pilocarpine-treated (n = 3) rats.
Single optical confocal images were acquired with Zeiss
LSM 5 Pascal laser-scanning microscope and analyzed
with the software provided by the microscope manufac-
turer (LSM 5 Examiner, Zeiss). All images were acquired
from the suprapyramidal blade of the dorsal and ventral
DG, using identical parameters for control and pilocarpine-
treated animals. The densities of labeling for VGLUT2
only and for VGLUT2–VGAT were estimated by counting
the number of positive pixels in each dentate gyrus (dorsal
and ventral) and in two regions of interests (ROIs): (1) the
granule cell layer (GCL) including the narrow zone
superficial to the granule cells defined as the supragranular
layer (SGL) and (2) the inner one-third of the molecular
layer (IML) as illustrated in Fig. 5b. For each channel, an
identical bottom threshold was applied throughout the
analyses, and only the pixels with a value above this
threshold were counted. When a pixel had a value above
the threshold in both channels, it was counted as double
positive. The number of counted pixels was reported to the
area of the ROI so that the variable shapes of the ROIs
drawn were not a source of bias. The average numbers of
pixels representing the average labeling densities for
VGLUT2 only and VGLUT2–VGAT (±SEM) were cal-
culated in each ROI for each group of control and 4-month
pilocarpine-treated rats. The data were analyzed statisti-
cally with a mixed model analysis of variance (ANOVA)
and Student’s t test.
In situ hybridization
Probe synthesis
The VGLUT2 probes used in this study were digoxigenin-
labeled riboprobes obtained by in vitro transcription of a rat
VGLUT2 cDNA (Gift from Dr S. El Mestikawy). This
cDNA (539 bp) was inserted into the pCR-TOPO-II vector
(Invitrogen) for in vitro transcription. The transcription was
carried out with the nonradioactive RNA labeling kit
(Roche Diagnostics, Meylan, France). The recombinant
plasmid containing the VGLUT2 cDNA insert was line-
arized with Xho I and transcribed with Sp6 RNA poly-
merase to obtain the antisense probe or linearized with
Hind III and transcribed with T7 to obtain the sense probe.
The labeling efficiency of the digoxigenin-labeled probes
for VGLUT2 mRNA was determined each time by direct
immunological detection on dot blots with a nucleic acid
detection kit (Roche Diagnostics). The intensity of the
signal for each probe was compared with a serial dilution
of digoxigenin-labeled control RNA of known concentra-
tion. Only antisense and sense VGLUT2 probes with
comparable signal intensity (comparable labeling effi-
ciency), as determined in dot blots, were used for in situ
hybridization.
Hybridization and detection
Free-floating sections from control (n = 3) and 2- to
4-month pilocarpine-treated (n = 6) rats were processed
for VGLUT2 in situ hybridization according to a previ-
ously described protocol (Esclapez et al. 1993; Boulland
et al. 2007). Briefly, after several pre-treatments to enhance
penetration of the probes, sections were incubated for 1 h
at RT in the pre-hybridization solution, and then overnight
at 50 C in the hybridization solution, consisting of the pre-
hybridization solution with the addition of 0.2 ng/ll
digoxigenin-labeled RNA probe, 100 mM dithiothreitol
(DTT) and 4 % dextran sulfate. After hybridization, sec-
tions were treated with ribonuclease A (50 lg/mL) for
30 min at 37 C following by low- to high-stringency
washes performed with decreasing concentrations of saline
sodium citrate solution (SSC), ending with an incubation in
0.19 SSC, 10 mM sodium thiosulfate for 30 min at 55 C.
Sections were then processed for immunodetection of the
digoxigenin label by means of a nucleic acid detection kit
(Roche Diagnostic). They were incubated overnight at 4 C
in alkaline phosphatase-conjugated sheep antibodies to
digoxigenin diluted 1:1,000, then in a chromogen solution
containing nitroblue tetrazolium (NBT) and 5-bromo-4-
chloro-3-indolyl phosphate (BCIP) reagents. The times in
the chromogen solution were determined according to
previously described protocols (Esclapez and Houser 1999;
Boulland et al. 2007). Sections from control and pilocar-
pine-treated animals were incubated in the chromogen
solution until optimal staining was achieved for VGLUT2
mRNA in each animal group (control and epileptic pilo-
carpine-treated rats). For VGLUT2 probe, the optimal
color reaction times (7.5 h) were similar for all sections
from all animal groups (control and pilocarpine-treated
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animals). In all experiments, the color reaction was stopped
by rinsing the sections in TB, pH 8.0 containing 1 mM
EDTA. Sections were then mounted on gelatin-coated
slides, dried and coverslipped in an aqueous mounting
medium (Crystal/Mount, Biomeda).
Results
Changes in VGLUT2 immunolabeling in the dentate
gyrus of pilocarpine-treated animals
The pattern of VGLUT2 immunohistochemical labeling in
the rat hippocampus has been reported previously (Fre-
meau et al. 2001; Herzog et al. 2001; Kaneko et al. 2002;
Halasy et al. 2004; Boulland et al. 2009; Soussi et al.
2010). Our study focused on the dentate gyrus (DG) where
the main differences were observed between control and
pilocarpine-treated rats. A detailed description of VGLUT2
immunolabeling through the entire rostro-caudal extent of
the DG was provided in control rats to compare to that of
pilocarpine-treated rats. All control animals, regardless of
their age, displayed the same patterns of immunolabeling
for VGLUT2. In these control animals, the VGLUT2 im-
munolabeling showed both laminar- and regional-specific
patterns within the DG (Fig. 1a–b0). At low magnification,
whereas moderate to strong VGLUT2 immunolabeling
were evident in the molecular and granule cell layers, very
low levels or virtually no labeling were observed in the
hilus and CA3c pyramidal cell layer, respectively, through
the entire rostral (Fig. 1a) to caudal (Fig. 1b) extent of the
DG. At higher magnification (Fig. 1a0, b0), the immuno-
histochemical labeling for VGLUT2 was characterized by
large punctate structures (arrows) and by a thin diffuse
labeling, as previously described (Fremeau et al. 2001;
Kaneko et al. 2002; Halasy et al. 2004). The large punctate
structures, observed through the entire rostro-caudal extent
of the hippocampus displayed, however, different patterns
of distribution along the dorsal to ventral axis of the DG.
Whereas in the dorsal DG, these large punctate structures
labeled for VGLUT2 were highly concentrated in the su-
pragranular layer (SGL) delineating this narrow region
superficial to the granule cells from the adjacent IML
(Fig. 1a0, arrows), in the ventral DG, they were dispersed
within SGL and adjacent IML (Fig. 1b0, arrows). These
VGLUT2-labeled punctate structures correspond mainly to
axon terminals from neurons located in the SuM (Boulland
et al. 2009; Soussi et al. 2010). The diffuse VGLUT2 im-
munolabeling, observed in the DG, displayed a similar
pattern of distribution along the rostro-caudal and dorso-
ventral axes of the hippocampus with higher levels of
labeling in the inner and outer one-third of the molecular
layer (Fig. 1a, b). These diffuse labeling in the inner and
outer one-third of the DG molecular layer has been sug-
gested to correspond to axon terminals originating from
hilar mossy cells and entorhinal cortex layer II/III neurons,
respectively (Halasy et al. 2004).
The pattern of VGLUT2 immunolabeling in the DG was
clearly different in all pilocarpine-treated animals at all
time intervals examined (Fig. 1c–j0) compared to that
observed in control rats (Fig. 1a–b0). The main differences
were observed in the IML and SGL and involved both
diffuse and large VGLUT2-containing terminal labeling.
Furthermore, these labeling patterns for VGLUT2 clearly
evolved following pilocarpine injection (Fig. 1c–j0). Thus,
at 1 week after pilocarpine injection (Fig. 1c–d0),
cFig. 1 Comparison of immunohistochemical labeling for VGLUT2
in coronal sections through the rostro-caudal extent of the dentate
gyrus from control (a, b0) and pilocarpine-treated animals at 1 week
(c, d0), 2 weeks (e, f0), 2 months (g, h0) and 12 months (i, j0). a0–j0
panels correspond to high magnification of the region outline in
panels a–j, respectively. a–b0 In a control rat, VGLUT2 immunola-
beling was present in the granular (G) and molecular (M) layers of the
dentate gyrus (DG) at rostral (a) and caudal (b) levels. Virtually no
labeling was observed in the hilus (H). At high magnification (a0, b0),
VGLUT2 labeling included both punctate structures (representative
examples pointed by arrows) and a diffuse labeling. The punctate
structures, presumed axon terminals from the supramammillary
nucleus neurons, displayed different patterns of distribution along
the dorsal to ventral axis of the dentate gyrus (a, b). These terminals
were concentrated in the supragranular layer (SGL) of the dorsal
region of DG (a0) and were much sparser distributed throughout the
inner molecular layer (IML) in the ventral DG (b0). The diffuse
immunolabeling for VGLUT2 was observed in the inner and outer
one-third of the molecular layer (a, b). c–c0 In a pilocarpine-treated
rat at 1 week, a decrease of the diffuse immunolabeling for VGLUT2
was evident in the IML of the dorsal (c, c0) but not in the ventral (d,
d0) DG. As in control (a0, b0), many VGLUT2-containing terminals
(arrows) were present in the SGL of the dorsal (c0) and ventral DG
(d0). e–f0 In a pilocarpine-treated rat at 2 weeks, the loss of VGLUT2
diffuse labeling was still evident in the IML of the dorsal DG (e, e0).
In addition to the numerous VGLUT2-containing terminals (arrows)
observed in the SGL, many of them were also present in the IML in
the dorsal DG (arrows; e0) and ventral IML (arrows; f0). g–h0 In an
epileptic pilocarpine-treated rat at 2 months, numerous VGLUT2-
containing terminals (arrows) were present in the entire IML
throughout the rostro-caudal (g, h0) extent of the DG. An apparent
recovery of diffuse labeling was observed in IML of the dorsal DG
(g0). i–j0 In an epileptic animal at 12 months, VGLUT2 immunola-
beling was clearly different from that observed in control and
pilocarpine-treated rats at 1 and 2 weeks but also from epileptic
animals at 2 months. VGLUT2-containing terminals displayed a
double-band distribution pattern, these terminals being located in the
SGL and in the uppermost part of the IML (arrows). A marked loss of
the diffuse immunolabeling for VGLUT2 was observed now
throughout the entire rostro-caudal level in the IML including in
the ventral dentate gyrus. H hilus, G granule cell layer, M molecular
layer, IML inner molecular layer, Ctrl control, Pilo 1 week pilocar-
pine-treated animal at 1 week after SE, Pilo 2 weeks pilocarpine-
treated animal at 2 weeks after SE, Pilo 2 months pilocarpine-treated
animal at 2 months after SE, Pilo 12 months pilocarpine-treated
animal at 12 months after SE. Scale bars 200 lm in a, c, e, g, i;
500 lm in b, d, f, h, j and 10 lm in a0–j0
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differences in the labeling patterns for VGLUT2 were
principally observed in the dorsal DG (Fig. 1c, c0). A loss
of diffuse VGLUT2 immunolabeling was evident in the
IML of the dorsal DG at both rostral (Fig. 1c, c0) and
caudal level (Fig. 1d). This loss contrasted with an appar-
ent increased labeling for large VGLUT2-containing ter-
minals in the SGL of the dorsal DG (Fig. 1c0, arrows)
compared with control animals (Fig. 1a0). Two weeks after
pilocarpine injection (Fig. 1e–f0), the loss of the diffuse
VGLUT2 immunolabeling in the IML was still evident in
the dorsal DG at both rostral (Fig. 1e, e0) and caudal
(Fig. 1f) levels. Furthermore, the labeling pattern for large
VGLUT2-containing terminals (arrows), in 2-week pilo-
carpine-treated animals, significantly differed from that
observed in control but also in 1-week pilocarpine-treated
rats. In addition to the numerous VGLUT2-containing
large boutons present in the SGL of the DG, many large
terminals were now observed in the IML. This aberrant
distribution pattern of large VGLUT2-containing terminals
in the IML was particularly obvious in the dorsal DG
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(Fig. 1e0) and contrasted with the restricted localization of
these terminals in the SGL in control (Fig. 1a0) and 1-week
pilocarpine-treated (Fig. 1c0) rats. An apparent increase of
the large VGLUT2-containing boutons was also observed
in the entire IML of the ventral DG in 2-week pilocarpine-
treated animals (Fig. 1f0, arrows) compared to control
(Fig. 1b0) and 1-week pilocarpine-treated (Fig. 1d0) rats.
All epileptic animals at 2 (Fig. 1g–h0) and 4 (not shown)
months after pilocarpine injection showed similar labeling
patterns for VGLUT2. These VGLUT2 labeling patterns
displayed marked differences with those from control
(Fig. 1a–b0) but also pilocarpine-treated animals at early
(1 week; Fig. 1c–d0) and late (2 weeks; Fig. 1e–f0) stages
of the latent period. The loss of diffuse labeling observed in
IML of the dorsal DG at 1 and 2 weeks was no longer
observed at this stage (compare Fig. 1g0 with Fig. 1c0, e0).
Furthermore, in these epileptic animals, numerous large
terminals labeled for VGLUT2 (arrows) invaded the entire
IML throughout all the rostro-caudal extent of the DG
(Fig. 1g–h0). This increased labeling of large VGLUT2-
containing terminals in the IML, compared with control,
1-week but also 2-week pilocarpine-treated animals, was
particularly prominent in the dorsal DG (compare Fig. 1g0
with Fig. 1a0, c0, e0), but was also evident in the ventral DG
(compare Fig. 1h0 with Fig. 1b0, d0, f0).
Interestingly, this dynamic reorganization of VGLUT2
immunolabeling observed during the latent period contin-
ued to evolve during the chronic stage. Epileptic rats
experiencing spontaneous seizures for several months
(pilocarpine-treated animals at 12 months) displayed an
aberrant labeling pattern for VGLUT2 in the IML of the
DG at all rostro-caudal levels examined (Fig. 1i–j), which
differed significantly from that of same-age control rats and
pilocarpine-treated rats during the latent but also from that
of epileptic animals at 2–4 months. Twelve-month pilo-
carpine-treated rats displayed main differences compared
to pilocarpine-treated animals at 2–4 months. These
included a complete loss of diffuse VGLUT2 immunola-
beling in the IML throughout the entire rostro-caudal
extent of the DG (Fig. 1i–j0) and a double-band distribution
pattern for large VGLUT2-containing terminals (arrows),
predominantly observed in the dorsal DG at rostral level
(Fig. 1i, i0). Indeed, at this level, the large VGLUT2-con-
taining terminals were mainly located in the SGL and in
the uppermost part of the inner one-third molecular layer
(Fig. 1i0, arrows). At caudal level (Fig. 1j, j0), VGLUT2-
containing terminals were distributed in the entire IML, but
mainly concentrated in the upper part of the inner one-third
molecular layer along the dorsal (Fig. 1j)–ventral (Fig. 1j,
j0, arrows) extent of the DG.
These aberrant VGLUT2-immunolabeling patterns in
pilocarpine-treated animals suggested a marked reorgani-
zation of DG afferents originating from SuM neurons.
Aberrant distribution of fibers and axon terminals
originating from SuM neurons in the DG
of pilocarpine-treated rats
To further test the above hypothesis, we investigated the
labeling pattern of supramammillary–dentate gyrus path-
ways in epileptic pilocarpine-treated rats at 2–4 months
and control animals using BDA anterograde tracer injected
in the SuM region. The labeling pattern of BDA-containing
fibers and axon terminals was examined in the DG of
control (n = 3) and epileptic pilocarpine animals (n = 6)
in which the BDA injection site included neurons from
both SuML and SuMM regions.
In control rats, many anterograde-labeled fibers and
axon terminals were observed in the dorsal (Fig. 2a,
arrows) and ventral (Fig. 2c, arrows) DG ipsilateral to the
injection site and to a lesser extent in the contralateral DG
(not shown). BDA-labeled fibers and terminals were
restricted to the SGL in the dorsal DG (Fig. 2a, arrows),
whereas they were slightly more dispersed within the SGL
and IML in the ventral DG (Fig. 2c, arrows). These data
are in keeping with previously described results (Haglund
et al. 1984; Vertes 1992; Maglo´czky et al. 1994; Soussi
et al. 2010).
Epileptic pilocarpine-treated animals displayed an
aberrant distribution pattern for BDA-containing fibers and
axon terminals compared to control rats. This was partic-
ularly evident in the dorsal DG in which relatively thick-
labeled fibers were giving rise to many thinner axonal
branches with numerous en passant boutons not only in the
SGL but throughout the entire IML (Compare Fig. 2b to
Fig. 2a). An aberrant distribution of BDA-containing fibers
and axon terminals was also observed in the ventral DG of
chronic pilocarpine-treated rats. Indeed, many fibers and
axon terminals were present in the uppermost part of the
IML in the ventral DG of chronic pilocarpine-treated but
not of control rats (compare Fig. 2d to Fig. 2c).
These results demonstrated a reorganization of the
SuM–DG pathways, which displayed a distribution pattern
in keeping with the reorganization of the large VGLUT2-
containing boutons within the dentate IML of epileptic
pilocarpine-treated animals.
Previous studies demonstrated in control rats the heter-
ogeneity of SuM–DG pathways with two main projections
originating from neurons in the SuML and the SuMM
(Haglund et al. 1984; Vertes 1992; Maglo´czky et al. 1994;
Vertes and McKenna 2000) that can be identified based on
their neurochemical content (Soussi et al. 2010). The axon
terminals from the SuML that innervate the SGL of the
dorsal DG and to a much lesser extent of the ventral DG
contain markers of both glutamatergic (VGLUT2) and
GABAergic (GAD65 and VGAT) neurotransmissions,
whereas the axon terminals from the SuMM that innervate
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exclusively the IML contain VGLUT2 only. To assess the
contribution of each pathway in the reorganization of the
SuM–DG projections, triple immunofluorescence labeling
for BDA, VGLUT2 and GAD65 were performed in the
dorsal (Fig. 3) and ventral (Fig. 4) regions of the DG in
epileptic and control rats.
In the dorsal DG of control rats, virtually all BDA-
containing terminals were located in the SGL (Fig. 3a) and
were labeled for GAD65 and VGLUT2 (Fig. 3a, g,
arrows), in keeping with previously reported data (Boul-
land et al. 2009; Soussi et al. 2010). The dorsal DG of
chronic pilocarpine-treated animals displayed aberrant
distribution of BDA-containing terminals not only from an
anatomical but also a neurochemical point of view. In the
dorsal DG of epileptic rats, BDA-containing terminals
were present in the IML, in addition to the SGL (Fig. 3h) in
contrast to control rats (Fig. 3a). Many of these BDA-
containing terminals were labeled for both GAD65 and
VGLUT2 (Fig. 3i–n, arrows) and some for VGLUT2 only
(Fig. 3i–n, arrowheads).
In the ventral DG of control animals, BDA-containing
terminals were distributed in the SGL and lower part of the
IML (Fig. 4a). These terminals included some boutons
which co-expressed VGLUT2 and GAD65 (Fig. 4b–g,
arrows) and boutons labeled for VGLUT2 only (Fig. 4b–g,
arrowheads). The ventral DG of chronic pilocarpine-treated
rats displayed a clear aberrant anatomical and neuro-
chemical labeling pattern for BDA-containing terminals
(Fig. 4h) as compared to that of control rats. This aberrant
pattern consisted mainly in the presence of numerous
Fig. 2 Comparison of the supramammillary–dentate gyrus pathways
in coronal sections of dorsal (a, b) and ventral (c, d) dentate gyrus
from control (a, c) and epileptic pilocarpine-treated animals (b,
d) revealed with BDA anterograde tracing. a–d In control as in
epileptic animals, the detection of BDA anterograde tracer was
performed 10 days after its injection in a region including both the
lateral and medial parts of the supramammillary nucleus (SuM). a,
c In a control rat, BDA-containing fibers and axon terminals (arrows)
were restricted to the supragranular layer (SGL) in dorsal DG (a),
whereas they were more distributed within the IML in the ventral DG
(c). b, d In an epileptic animal at 2 months after pilocarpine injection,
an aberrant distribution of BDA-containing fibers and axon terminals
was evident. In the dorsal DG (b), these fibers and axon terminals
(arrows) were located not only in the SGL as in a control rat but also
invaded the entire IML (compare with panel a). In the ventral DG (d),
many BDA-containing fibers and axon terminals (arrows) were also
observed in the uppermost part of the IML in contrast to control
animal (compare with panel c). DG dentate gyrus, G granule cell
layer, SGL supragranular layer, IML inner molecular layer, Ctrl
control, Pilo 2 months pilocarpine-treated rat at 2 months after status
epilepticus. Scale bar 20 lm
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BDA-containing boutons located in the uppermost part of
the IML. Most of these boutons co-expressed GAD65 and
VGLUT2 (Fig. 4i–n, arrows), whereas some were only
labeled for VGLUT2 (Fig. 4i–n, arrowhead). Furthermore,
many BDA-containing terminals labeled for VGLUT2 as
well as VGLUT2-containing boutons were evident
throughout the entire IML of the ventral DG in epileptic
animals (Fig. 4h).
Altogether, these results demonstrated an aberrant dis-
tribution of fibers and axon terminals originating from
Fig. 3 Comparison of neurochemical phenotypes for the dorsal
dentate gyrus afferents from the SuM between control (a–g) and
epileptic pilocarpine-treated (h–n) rats, characterized by simultaneous
labeling for BDA anterograde tracer (green), GAD65 (red) and
VGLUT2 (blue) in coronal sections. a Image corresponding to a
maximum intensity projection of a confocal slice z-stack (22 optical
slices, spaced at 285 nm) showing labeling for BDA (green), GAD65
(red) and VGLUT2 (blue) in the dorsal DG of a control rat. Axon
terminals and fibers, originating from SuM neurons and labeled for
the BDA anterograde tracer (green), were located mainly in the SGL.
Numerous GAD65-containing terminals (red) were present in the
IML and SGL. VGLUT2-containing terminals (blue) were mainly
located in the SGL. b–d Images of the three different fluorophores
used for the triple labeling, obtained by sequential acquisition of
separate wavelength channels from a single confocal slice in the SGL
of the dorsal DG demonstrated that many if not all axon terminals
labeled for BDA (b, green, arrows) contained GAD65 (c, red,
arrows) and VGLUT2 (d, blue, arrows). e Merge of b and c. f Merge
of b and d. g Merge of b–d. Triple-labeled boutons for BDA, GAD65
and VGLUT2 (white, arrows) were surrounded by double-labeled
terminals for GAD65 and VGLUT2 (purple) as well as single-labeled
terminals for GAD65 (red) or VGLUT2 (blue). h Image
corresponding to a maximum intensity projection of a confocal slice
z-stack (22 optical slices, spaced at 285 nm) showing labeling for
BDA (green), GAD65 (red) and VGLUT2 (blue) in the dorsal DG of
an epileptic rat at 2 months after pilocarpine injection. Axon
terminals and fibers, originating from SuM neurons, labeled for the
BDA anterograde tracer (green) were distributed within the entire
IML in contrast to the control rat (compare with panel a). Numerous
GAD65-containing terminals (red) were present in the IML and SGL.
VGLUT2-containing terminals (blue) were located in the SGL but
also in all the IML. i–k Images of the three different fluorophores
used for the triple labeling, obtained by sequential acquisition of
separate wavelength channels from a single confocal slice, in the IML
of the dorsal DG demonstrated two types of BDA-labeled axon
terminals (i, green): the first one contained GAD65 (j, red, arrow) and
VGLUT2 (k, blue, arrow), the second one contained VGLUT2 only
(i–k, arrowhead). l Merge of i and j. m Merge of i and k. n Merge of
i–k. Triple-labeled boutons for BDA, GAD65 and VGLUT2 (white,
arrow) were surrounded by double-labeled terminals for BDA and
VGLUT2 (arrowhead) as well as single-labeled terminals for GAD65
(red) or VGLUT2 (blue). Ctrl control, Pilo 2 months pilocarpine-
treated rat at 2 months after status epilepticus. Scale bars 10 lm in
a and h; 2 lm in b–g and i–n
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Fig. 4 Comparison of neurochemical phenotypes for the ventral
dentate gyrus afferents from the SuM between control (a–g) and
epileptic pilocarpine-treated (h–n) rats, characterized by simultaneous
labeling for BDA anterograde tracer (green), GAD65 (red) and
VGLUT2 (blue) in coronal sections. a Image corresponding to a
maximum intensity projection of a confocal slice z-stack (40 optical
slices, spaced at 300 nm) showing labeling for BDA (green), GAD65
(red) and VGLUT2 (blue) in the ventral DG of a control rat. Axon
terminals and fibers, originating from the SuM neurons, labeled for
the BDA anterograde tracer (green) were distributed in the SGL and
in the lower part of the IML. Numerous GAD65-containing terminals
and VGLUT2-containing terminals were present in this region. b–
d Images of the three different fluorophores used for the triple
labeling, obtained by sequential acquisition of separate wavelength
channels from a single confocal slice, in the SGL of the ventral DG
demonstrated axon terminals labeled for BDA (b, green, arrows)
containing GAD65 (c, red, arrows) and VGLUT2 (d, blue, arrows)
and BDA-labeled terminals containing VGLUT2 only (d, blue,
arrowheads). e Merge of b and c. f Merge of b and d. g Merge of b–
d. Triple-labeled boutons for BDA, GAD65 and VGLUT2 (white,
arrows) and double-labeled boutons for BDA and VGLUT2 (arrow-
heads) were surrounded by double-labeled terminals for GAD65 and
VGLUT2 (purple) as well as single-labeled terminals for GAD65
(red) or VGLUT2 (blue). h Image corresponding to a maximum
intensity projection of a confocal slice z-stack (40 optical slices,
spaced at 300 nm) showing labeling for BDA (green), GAD65 (red)
and VGLUT2 (blue) in the ventral DG of an epileptic rat at 2 months
after pilocarpine injection. Axon terminals and fibers, originating
from SuM neurons, labeled for the BDA anterograde tracer (green)
displayed an aberrant distribution as compared to the control rat (a),
many boutons and fibers being observed in the entire IML including
the upper part. Numerous GAD65-containing terminals (red) and
VGLUT2-containing terminals (blue) were also present in this entire
region. i–k Images of the three different fluorophores used for the
triple labeling, obtained by sequential acquisition of separate
wavelength channels from a single confocal slice, in the IML of the
ventral DG demonstrated that many of these ectopic BDA-labeled
axon terminals (i, green, arrows) contained GAD65 (j, red, arrows)
and VGLUT2 (k, blue, arrows) and some contained VGLUT2 only
(i–k arrowhead). l Merge of i and j. m Merge of i and k. n Merge of i–
k. Triple-labeled boutons for BDA, GAD65 and VGLUT2 (white,
arrows) and double-labeled terminals for BDA and VGLUT2
(arrowhead) were surrounded by double-labeled terminals for
GAD65 and VGLUT2 (purple) as well as single-labeled terminals
for GAD65 (red). Ctrl control, Pilo 2 months pilocarpine-treated rat at
2 months after status epilepticus. Scale bars 10 lm in a and h; 2 lm
in b–g and i–n
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neurons of the SuML but also SuMM in epileptic pilo-
carpine-treated rats.
Quantitative analysis of the changes in VGLUT2
and colocalized VGAT and VGLUT2 axon terminal
labeling levels in epileptic animals
To estimate whether the reorganization of DG afferents
originating from the SuML and SuMM corresponded to a
dispersion and/or an increased number of boutons, a quan-
titative analysis of VGLUT2/VGAT- and of VGLUT2-
labeled boutons were performed in the entire granule cells
layer (GCL) including the supragranular layer (SGL) and in
the IML of the dorsal and ventral DG in 4-month pilocar-
pine-treated (n = 3) and control rats (n = 3). Quantitative
data (Fig. 5a) showed that, in epileptic rats, the average
densities (number of pixel/lm2) of VGLUT2/VGAT
labeling were significantly increased, compared to control
animals, in the IML (?814 %; Pilo: 5.21 ± 0.43; Ctrl:
0.57 ± 0.2; p\ 0.001) and GCL/SGL (?73 %; Pilo:
5.30 ± 0.75; Ctrl: 3.07 ± 0.7; p\ 0.01) of the dorsal DG
as well as in the IML (?299 %; Pilo: 6.22 ± 1.08; Crtl:
1.56 ± 0.48; p\ 0.05) of the ventral DG. No difference
was found in the GCL/SGL of the ventral DG (Pilo:
4.33 ± 0.63; Ctrl: 5.78 ± 1.09). The average densities of
VGLUT2 labeling were significantly increased in the IML
of the dorsal (?93 %; Pilo: 5.65 ± 0.59; Ctrl: 2.93 ± 0.59;
p\ 0.01) and ventral (?70 %; Pilo: 14.91 ± 1.57; Ctrl:
8.75 ± 1.56, p\ 0.01) DG and significantly decreased in
the GCL/SGL of the ventral DG (-35 %; Pilo:
3.94 ± 0.32; Ctrl: 6.11 ± 0.92; p\ 0.05) of epileptic
compared to control animals. The average densities of
VGLUT2 labeling were not significantly different in the
GCL/SGL of the dorsal DG between epileptic (3.69 ± 0.35)
and control (4.63 ± 0.66) rats.
These results demonstrated an overall increased density
of labeling for terminals displaying SuML (VGLUT2/
VGAT) as well as SuMM (VGLUT2) neurochemical
phenotypes within the dentate IML of chronic pilocarpine-
treated animals.
Granule cells did not express VGLUT2 in control
and pilocarpine-treated animals
Sprouting of mossy fibers, the axons of dentate granule
cells, in the IML of pilocarpine-treated rats is well estab-
lished (Okazaki et al. 1995; Okazaki and Nadler 2001;
Buckmaster et al. 2002). Even though in adult rodent brain,
VGLUT1 appears to be the only vesicular glutamate
transporter expressed by dentate granule cells (Fremeau
et al. 2001; Herzog et al. 2001; Kaneko et al. 2002; Fre-
meau et al. 2004; Herzog et al. 2006), a transient VGLUT2
expression by granule cells at early postnatal
developmental stages, that rapidly decreases with age, was
reported in mouse (Fremeau et al. 2004; Herzog et al.
2006). We therefore investigated whether the aberrant
pattern of VGLUT2 labeling in the IML could partly reflect
an ectopic expression of VGLUT2 by dentate granule cells
in pilocarpine-treated rats. Nonradioactive in situ hybrid-
ization experiments for the detection of VGLUT2 mRNA
with antisense probes demonstrated very low levels of
labeling in all principal layers of the hippocampus
including the pyramidal and dentate granule cell layers of
control (Fig. 6a) as well as pilocarpine-treated animals
(Fig. 6b). These low levels of labeling were similar to that
observed with sense probes in pilocarpine-treated (Fig. 6c)
or control (not shown) rats and therefore corresponded to
nonspecific labeling. Whereas no detectable specific
labeling was observed in the dorsal DG, hilar neurons in
the ventral DG displayed low levels of VGLUT2 mRNA
(Fig. 6d). This low level of mRNA in the hilar neurons of
the ventral DG contrasted with the moderate to high levels
of VGLUT2 mRNA labeling observed in the SuML and
SuMM of pilocarpine-treated animals (Fig. 6f, f0) and
control rats (Fig. 6e, e0). In both animal groups, VGLUT2
mRNA-expressing neurons within the SuM displayed
comparable levels of labeling, using the antisense probes,
whereas no labeling was observed with the sense control
probes (Fig. 6g).
These results demonstrated that dentate granule cells did
not express VGLUT2 mRNA in control as well as in epi-
leptic pilocarpine-treated rats.
Aberrant distribution of VGLUT2 immunolabeling
is not related with granule cell dispersion or
bi-lamination
Granule cells dispersion and bi-lamination have been
described in humans with mesial temporal lobe epilepsy as
well as in experimental animal models (Houser 1990;
Mello et al. 1993; Haas et al. 2002; Chai et al. 2013). We
therefore investigated whether the aberrant distribution of
VGLUT2-containing axon terminals in the dentate IML of
pilocarpine-treated animals including the double-band
distribution observed in 12-month epileptic animals could
result from a dispersion or a bi-lamination of granule cells.
The distribution pattern of VGLUT2 immunolabeling
associated with that of NeuN-labeled dentate granule cells
was analyzed in control (Fig. 7a, b) and pilocarpine-treated
animals at 2 weeks (Fig. 7c, d), 2 months (Fig. 7e, f) and
12 months (Fig. 7g, h). No dispersion or bi-laminar orga-
nization of dentate granule cells correlated with the aber-
rant pattern of VGLUT2-containing terminals in the IML
of all pilocarpine-treated rats examined (Fig. 7c–h). The
thickness of the dentate granule cell layer was relatively
similar in control and pilocarpine-treated rats, even though
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dentate granule cells in pilocarpine-treated animals dis-
played a decreased labeling intensity for NeuN (Fig. 7c–h)
compared to control rats (Fig. 7a, b). Virtually no NeuN-
labeled cell body was evident in the IML of pilocarpine-
treated animals displaying increased number of VGLUT2-
containing terminals at 2 weeks (Fig. 7c, d), 2 months
(Fig. 7e, f) and 12 months (Fig. 7g, h) after pilocarpine
injection.
Fig. 5 Quantitative analysis of VGLUT2 and VGAT proteins. a,
b Quantitative analysis of the mean densities of labeling for VGLUT2
only and for VGLUT2/VGAT performed for the dorsal and ventral
DG, in two regions of interest drawn over the inner molecular layer
(IML) and granule cell layer which included the supragranular layer
(GCL/SGL) as illustrated in (b) of the suprapyramidal blade (Sup.bl).
Measures were obtained from three controls (white rectangles) and
three pilocarpine-treated rats at 4 months (gray rectangles). Statisti-
cally significant differences are indicated (*p\ 0.05; **p\ 0.01;
***p\ 0.001; ANOVA test). Errors bars SEM
Fig. 6 Comparison of labeling forVGLUT2mRNA in coronal sections
of hippocampal formation (a–d) and of the SuM(e–g) fromcontrol (a,d,
e) and epileptic pilocarpine-treated rats (b, c, f, g), processed for the
same color reaction time. Sections of the hippocampal formation from a
control rat (a) and an epileptic rat at 2 months (b), processed with
antisense RNA probe, showed a faint nonspecific labeling for VGLUT2
in the pyramidal and granule cell layers similar to that observed in a
section from an epileptic rat processed for the control sense RNA probe
(c). d A section of the hippocampal formation, at a caudal level in a
control rat, showing that hilar neurons, presumed mossy cells, in the
ventral DG (vDG) expressed low levels of VGLUT2 mRNA as
compared to mesencephalic nuclei including the red nucleus (RN) and
the medial geniculate (MG). Hilar neurons in the dorsal DG (dDG) did
not display detectable level of VGLUT2 mRNA. e In a section from a
control rat, processed with antisense RNA probe, VGLUT2mRNAwas
expressed by many diencephalic neurons including neurons located in
the medial part (SuMM) and lateral part (SuML) of the supramamm-
illary nucleus (SuM) as illustrated at higher magnification in the inset
(e0). f In a section from an epileptic rat at 2 months after pilocarpine
injection, processed with antisense RNA probe, revealed similar pattern
and intensity of labeling for VGLUT2 mRNA in the SuMM and SuML
(see inset f0) as that observed in the control rat (compare with e, e0). g No
labeling was observed in an adjacent section from an epileptic rat at
2 months after pilocarpine injection, processed with sense RNA probe.
Ctrl control, Pilo 2 months pilocarpine-treated rat at 2 months after
status epilepticus. Scale bars 100 lm in e f, g; 25 lm in e0, f0; 50 lm in
a–c; 500 lm in d
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Fig. 7 Synaptic targets of ectopic dentate gyrus afferents from SuM
neurons in pilocarpine-treated rats. a–h Comparison of distribution
patterns of VGLUT2-containing terminals (brown) and NeuN-labeled
dentate granule cells (red) in coronal sections of the dorsal DG from a
control rat (a, b) and pilocarpine-treated animals at 2 weeks (c, d),
2 months (e, f) and 12 months (g, h). b, d, f, h High magnifications of
outlined areas, respectively, illustrated in panels a, c, e and g. In
pilocarpine-treated rats (c–h), the distribution pattern of dentate
granule cell somata was similar to that observed in the control animal
(a, b). No dispersion or bi-lamination of granule cells was associated
with the aberrant VGLUT2-immunolabeling observed in the IML in
pilocarpine-treated rat from 2 weeks on. i A section of dorsal DG
from an epileptic animal at 2 months that was injected into the CA3
stratum lucidum of the dorsal hippocampus with the Rabies virus
(RV) retrograde tracer to label cell bodies and dendritic trees of
dentate granule cells (G). j–k Image corresponding to a maximum
intensity projection of a confocal slice z-stack (20 optical slices,
spaced at 296 nm) showing labeling for the RV (green), VGAT (red)
and VGLUT2 (blue) in the dorsal dentate gyrus of an epileptic rat at
2 month after pilocarpine injection. j High magnification of the region
indicated by an arrow and a star in panel (i). Presumed axon terminals
from SuM neurons, labeled for VGAT and VGLUT2, displayed an
aberrant distribution with many boutons present in the entire IML
including the upper part. Note that in the epileptic rat, the proximal
apical dendrites (arrow) of dentate granule cells (*) across the IML
displayed a low number of spines as compared to more distal
segment. k Higher magnification of the outlined region indicated in
panel j showing a dendritic tree of dentate granule cell across the
upper IML contacted by ectopic VGLUT2/VGAT-containing axon
terminals. l, m Images of the three different fluorophores used for the
triple labeling, obtained by sequential acquisitions of separate
wavelength channels from a single confocal slice, in the two outlined
regions of the IML indicated in panel k and demonstrating that
ectopic axon terminals labeled for VGAT (red, arrowhead) and
VGLUT2 (blue, arrowhead), presumably originating from the SuM
establish contact on the dendritic shafts of dentate granule cells
retrogradely labeled with rabies virus (green). Scale bars 200 lm in
a, c, e and g; 50 lm in b, d, f and h; 100 lm in i; 15 lm in j; 1 lm in
k; 0.5 lm in l, m
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Synaptic targets of ectopic VGLUT2/VGAT-
and VGLUT2-containing boutons within the IML
of epileptic rats
The synaptic targets of aberrant VGLUT2/VGAT- and
VGLUT2-containing axon terminals in the dentate IML of
pilocarpine-treated animals were investigated. Retrograde
labeling with Rabies virus resulting in a Golgi-like label-
ing of the dendritic arbor of dentate granule cells (Fig. 7i)
revealed that in epileptic pilocarpine-treated rats, the
proximal dendrites of these cells across the IML displayed
a few number of spines as compared to more distal seg-
ment (Fig. 7j). Along the IML, these spine-free dendritic
trees were contacted by many ectopic VGLUT2/VGAT-
and VGLUT2-containing axon terminals (Fig. 7k, l, m,
arrows).
Discussion
This study demonstrates a marked reorganization of DG
afferents from neurons of the SuM in the pilocarpine model
of MTLE. This reorganization, characterized by an aber-
rant distribution and an increased number of fibers and
axons terminals from neurons of the SuML and the SuMM
within the entire IML of the DG, most likely results from
sprouting of these SuM–DG afferents. The aberrant con-
nections formed by SuM neurons within the IML of the DG
which start to appear during the latent period and are
numerous when animals display spontaneous seizures
could contribute along with the reorganization of hippo-
campal intrinsic networks to the emergence of spontaneous
seizures.
General considerations
Our data demonstrate two patterns for VGLUT2 immu-
nohistochemical labeling in control rats in keeping with
previous studies using identical or different antibodies for
VGLUT2 detection (Fremeau et al. 2001; Halasy et al.
2004). The first one corresponds to large punctate struc-
tures, and the second one to a diffuse and thin labeling.
Whereas it is now demonstrated that the large punctate
structures, located in the supragranular layer of the DG,
correspond for a large majority to axon terminals from
SuM neurons (Boulland et al. 2009; Soussi et al. 2010),
the specificity and origin of the diffuse labeling is debated
(Halasy et al. 2004). However, it was suggested that this
diffuse labeling for VGLUT2 observed in the IML of the
DG could correspond to the axon terminals of glutama-
tergic mossy cells (Halasy et al. 2004). Several of our
results support this hypothesis. The first one is provided
by our in situ hybridization experiments showing that
hilar neurons in the ventral DG of control rats express
low levels of VGLUT2 mRNA despite no detectable level
is evident for hilar neurons of the dorsal DG. The second
set of data, supporting this hypothesis, is the loss of the
VGLUT2 diffuse thin labeling in the IML of the dorsal
DG observed during the latent period at 1 and 2 weeks
after pilocarpine-induced status epilepticus. Such loss is
well correlated with the death of hilar glutamatergic
mossy cells and associated axon terminals in the IML of
the dorsal DG, reported in many experimental models of
temporal lobe epilepsy (Sloviter 1987; 1991; Lowenstein
et al. 1992; Sloviter et al. 2003; Zappone and Sloviter
2004; Kienzler et al. 2009), including the pilocarpine
model (Obenaus et al. 1993; Buckmaster et al. 2002;
Ferhat et al. 2003; Sloviter et al. 2003; Boulland et al.
2007; Sbai et al. 2012). The transient recovery of this loss
of diffuse labeling at 2–4 months is in keeping with
partial compensation provided by remaining mossy cells
including from the ventral DG. The striking loss of
VGLUT2 diffuse labeling observed in the IML of the DG
at 12 months after pilocarpine treatment is likely to reflect
further degeneration of mossy cells including those from
the ventral DG observed in epileptic animals experiencing
severe seizures (for review see Kienzler et al. 2009) as
well as in patients suffering from mesial temporal lobe
epilepsy (Blu¨mcke et al. 2000).
Reorganization of SuM–DG pathways
Our data demonstrate a marked reorganization of DG
extrinsic afferents from the SuM. Such reorganization,
which starts during the latent period, is massive at
2–4 months after pilocarpine injection, when animals dis-
play frequent spontaneous seizures, and continues to
evolve after several months of seizures. This reorganization
is illustrated by an aberrant distribution of large VGLUT2-
containing terminals in regions that are not innervated in
control rats. The SuM origin of these large VGLUT2-
containing terminals displaying ectopic distribution within
the entire IML of epileptic animals is supported by our
following results: (1) An aberrant distribution of antero-
gradely labeled BDA-containing terminals from SuM
neurons demonstrated by the presence of fibers and ter-
minals in the entire IML of epileptic pilocarpine animals
instead of being restricted to the SGL as in control rats; (2)
Many if not all BDA-containing terminals with ectopic
localization display the neurotransmitter phenotype of
terminals from SuML neurons which co-express VGLUT2
and GAD65 or VGAT or phenotype from SuMM neurons
expressing VGLUT2 only (Boulland et al. 2009; Soussi
et al. 2010).
Furthermore, our data strongly suggest that none of the
aberrant VGLUT2-containing terminals correspond to the
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terminals of mossy fibers, the axons of glutamatergic
granule cells, known to sprout and form ectopic connec-
tions within the IML of the pilocarpine model (Mello et al.
1993; Okazaki et al. 1995; Buckmaster et al. 2002). Indeed,
our in situ hybridization experiments do not provide evi-
dence for aberrant expression of VGLUT2 mRNA by
granule cells in pilocarpine-treated animals. The levels of
labeling in all pilocarpine-treated and control rats obtained
with antisense probes were similar to that found with
control sense probes. Therefore, we conclude that dentate
granule cells do not express VGLUT2 mRNA either in
adult control or pilocarpine-treated rats. VGLUT1 appears
to be the only vesicular glutamate transporter expressed by
granule cells in adult naive (Fremeau et al. 2001; Herzog
et al. 2001) and epileptic rats (Boulland et al. 2007).
Reorganization results from sprouting of axon terminals
from SuML and SuMM neurons
Our study provides evidence that in epileptic animals, the
aberrant distribution of axon fibers and terminals from SuM
neurons innervating the IML of the DG is due to an
increased number of axon terminals instead of a dispersion
of pre-existing ones. First of all, the emergence of a
VGLUT2/VGAT labeling within the IML of the entire DG
in these animals, associated with an increase of this
labeling within the GCL/SGL, as demonstrated by the
quantitative analysis strongly supports an increase of the
number of VGLUT2/VGAT-containing boutons originat-
ing from the SuML instead of a dispersion of these boutons
from the GCL/SGL, in which they are located in control
rats (Boulland et al. 2009; Soussi et al. 2010). We cannot
completely exclude that part of the increased labeling
density observed within the GCL/SGL of the dorsal DG
reflects an increase in protein levels within terminals
instead of an increased number of boutons within this layer.
However, our in situ hybridization experiments do not
support high increases of VGLUT2 synthesis in epileptic
animals since similar levels of VGLUT2 mRNA was
observed in the SuM of control and epileptic rats. There-
fore, the massive increase of VGLUT2/VGAT labeling
observed within the IML most likely results from newly
formed boutons due to a sprouting of axonal branches and
terminals from the SuML invading the IML of the entire
DG.
Furthermore, our results demonstrate in the epileptic
animals a marked increased labeling for VGLUT2 not only
in the IML of the ventral but also of the dorsal DG,
whereas VGLUT2 labeling was slightly decreased or not
modified in the granule cell layer of the ventral and of the
dorsal DG, respectively. In naı¨ve rats, axon terminals,
containing VGLUT2 only, originate mainly from the
SuMM (Soussi et al. 2010), and these afferents from the
SuMM innervate the ventral but not the dorsal DG (Mag-
lo´czky et al. 1994). Therefore, the marked increased
labeling for VGLUT2 in the IML of the entire DG strongly
suggests that fibers and axon terminals from the SuMM do
not only sprout in the ventral DG but also invade the IML
of the dorsal DG. This is further supported by anterograde-
tracing experiments showing, within the IML of the dorsal
DG in epileptic animals, BDA-containing terminals labeled
for VGLUT2 only in addition to many terminals co-labeled
for VGLUT2 and GAD65 (originating from the SuML).
Our experiments cannot exclude completely that addi-
tional sources of origin could contribute to the increased
number of VGLUT2-containing terminals in the DG of
epileptic rats. However, in naı¨ve rat, the SuM is the major
source for VGLUT2-containing large terminals innervating
the DG. Indeed, despite the suggestion that VGLUT2-con-
taining neurons of the medial septum/diagonal band com-
plex (MS/DB) could innervate the DG (Colom et al. 2005),
DG afferents from the MS/DB are almost exclusively cho-
linergic and GABAergic (Nyakas et al. 1987; Freund and
Antal 1988; Gaykema et al. 1990). None of these cholinergic
or GABAergic neurons contains VGLUT2 (Gritti et al.
2006). Similarly, serotoninergic neurons from the medial
raphe innervating the DG (Conrad et al. 1974; Vertes et al.
1999) do not express VGLUT2 mRNA but VGLUT3 (Gras
et al. 2002; Herzog et al. 2004). Furthermore, there is no
evidence that neurons from the deep layers (IV–VI) of the
entorhinal cortex known to project within all molecular
layer, including the IML, in the ventral DG (Deller et al.
1996; Deller 1998) express VGLUT2 (Halasy et al. 2004).
Finally, neurons of the thalamic nucleus reuniens which
express VGLUT2 mRNA (Barroso-Chinea et al. 2007) are
known to provide strong innervations to the hippocampal
formation; however, their axons form large boutons within
the stratum lacunosum of CA1 and not the DG (Wouterlood
et al. 1990; Hoover and Vertes 2012). Several cells scattered
within various hypothalamic nuclei including the tubero-
mammillary nucleus and the lateral hypothalamic area have
been reported to project to the hippocampal formation
(Haglund et al. 1984; Ko¨hler et al. 1984; Ko¨hler et al. 1985;
Maglo´czky et al. 1994). Whereas these nuclei are likely to
innervate the CA2/CA3 regions of the hippocampus, the
innervation of the dentate IML as the neurochemical content
for VGLUT2 has to be demonstrated. Thus, in the epileptic
animals, the increased densities of VGLUT2- and VGLUT2/
VGAT-containing boutons invading the IML of the entire
DG are likely to be provided mainly by SuMM and SuML
neurons.
All together, our data provide strong evidences for an
actual sprouting of axon terminals from SuML and SuMM
neurons in pilocarpine-induced epileptic animals as previ-
ously suggested in human MTLE (Maglo´czky et al. 2000)
and the related kainate model (Skyers et al. 2003).
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Functional consequences of reorganization of SuM–DG
pathways
Our results also demonstrate that the reorganization of
SuM–DG including the aberrant distribution and increased
densities of fibers and axon terminals from SuML and
SuMM neurons within the IML of DG follows the temporal
development of epilepsy. It starts during the latent period,
becomes significant at the end of this period/beginning of
the chronic stage when seizure onset occurs (El-Hassar
et al. 2007) and is massive when the frequency of spon-
taneous seizures reaches a plateau and stabilizes around
2 months after pilocarpine injection (unpublished data),
similarly to that described in the kainate-induced seizures
model (Williams et al. 2009). This reorganization likely
leads to an aberrant connectivity between the SuM and the
DG with ectopic and/or newly formed axon terminals tar-
geting different subcellular compartments than in the
control rats. In control rats, axon terminals from the SuML
innervate the cell bodies and adjacent proximal apical
dendrites of dentate granule cells (Maglo´czky et al. 1994,
2000; Boulland et al. 2009; Soussi et al. 2010). We show
that in epileptic animals, the ectopic axon terminals from
the SuML, including those showing a double-band orga-
nization, establish presumed synaptic contacts all along
dentate granule cell dendrites across the entire IML.
The direct functional consequences of this aberrant
connectivity and therefore its contribution to epilepto-
genesis or ictogenesis are clearly speculative and deserve
specific studies that are beyond the scope of this work.
However, it is tempting to speculate that such reorganiza-
tion could facilitate the emergence of spontaneous seizures
since the time course of its development follows the
emergence and stabilization of the epilepsy. In keeping
with this hypothesis, Saji et al. (2000) reported that tran-
sient silencing of SuM–hippocampal pathways, performed
by injection of muscimol, an agonist of GABA-A receptor
into the SuM prevents the genesis and spread of sponta-
neous seizures in a rat model of kainic acid-induced sei-
zures. Anyway, the physiological consequences of such
structural reorganization have to be understood in order to
access its potential implication in the epileptic zone.
Conclusion
Our findings provide evidence for a marked reorganization
of both SuM–DG pathways originating from SuML and
SuMM neurons in epileptic pilocarpine-treated animals.
The reorganization, which reflects axon terminals sprout-
ing, leads to an aberrant connectivity that could play a role
in triggering spontaneous seizure according to the emo-
tional and cognitive state of the subject.
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